ESTRO 2023 - Abstract Book

S489

Sunday 14 May 2023

ESTRO 2023

Results Of the EMBRACE II patients included, 768 patients fulfilled the criteria at the time of longitudinal analysis. “A little or worse” late persistent PN was experienced by 40.2% (n=309) and “quite a bit or worse” by 9.5% (n=75) of patients in at least half of FUPs. Among patients with late persistent “a little or worse” and “quite a bit and worse” PN 8.5% and 1%, respectively, did not experience any worsening compared to the baseline condition. Figure2.a shows different clusters of patients identified by TJA among the 768 patients. Figure2.b shows the clusters identified only in patients with “a little or worse” late persistent PN (n=309). In both scenarios, TJA found three major clusters of patients with similar time development patterns: progressing to “a little”, progressing to “very much”, and transient PN. A small group of patients did not show worsening compared to the baseline condition.

Conclusion Patient-reported tingling and numbness in hands and feet was experienced frequently after treatment by LACC patients in EMBRACE II. TJA allowed to identify major clusters of patients with clear worsening of PN over time, most of them reporting “a little”. Because of the impact of PN on long-term QoL and activities of daily life of cancer survivors, further efforts should be directed at understanding this symptom, identifying risk factors and potential strategies for reduction. OC-0606 Severity and time-weighted gastrointestinal morbidity in cervix cancer: EMBRACE analysis with MOSES M. Charnalia 1,2 , N. Ranjan 3 , S. Spampinato 4 , R. Pötter 5 , I.M. Jürgenliemk-Schulz 6 , N. Nesvacil 7 , K. Kirchheiner 5 , K. Tanderup 8 , S. Chopra 2 1 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark; 2 Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute , Radiation Oncology, Navi Mumbai, India; 3 Assam Cancer Care Foundation, Radiation Oncology, Guwahati, India; 4 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark; 5 Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria; 6 University Medical Centre Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands; 7 Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria; 8 Aarhus University Hospital, Danish Center for Particle Therapy , Aarhus, Denmark Purpose or Objective This report describes the impact of incidence, severity and duration of late gastrointestinal (GI) morbidity after radiochemotherapy on Quality of Life (QoL) in locally advanced cervix cancer patients using the Months and Severity Score (MOSES) method.

Materials and Methods